Literature DB >> 25427992

Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Carlo Perricone1, Fulvia Ceccarelli, Gideon Nesher, Elisabetta Borella, Qasim Odeh, Fabrizio Conti, Yehuda Shoenfeld, Guido Valesini.   

Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune condition characterized by low platelet count with mucocutaneous and other bleedings. Clinical manifestations may range from spontaneous formation of purpura and petechiae, especially on the extremities, to epistaxis, bleeding at the gums or menorrhagia, any of which occur usually if the platelet count is below 20,000 per μl. A very low count may result in the spontaneous formation of hematomas in the mouth or on other mucous membranes. Fatal complications, including subarachnoid or intracerebral, lower gastrointestinal or other internal bleeding can arise due to an extremely low count. Vaccines may induce ITP by several mechanisms. Vaccine-associated autoimmunity may stem not only from the antigen-mediated responses but also from other constituents of the vaccine, such as yeast proteins, adjuvants, and preservatives diluents. The most likely is through virally induced molecular mimicry. The binding of pathogenic autoantibodies to platelet and megakaryocytes may cause thrombocytopenia by different mechanisms, such as opsonization, direct activation of complement, or apoptotic pathways. The autoantibodies hypothesis is not sufficient to explain all ITP cases: In the anti-platelet antibody-negative cases, a complementary mechanism based on T cell immune-mediated mechanism has been suggested. In particular, T cell subsets seem dysregulated with an increased production of pro-inflammatory cytokines, as IFN-γ and TNF, and chemokines, as CXCL10. Vaccines are one of the most striking discoveries in human history that changed dramatically life expectancy. Nonetheless, the occurrence of adverse events and autoimmune phenomena has been described following vaccination, and ITP may represent one of this.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427992     DOI: 10.1007/s12026-014-8597-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  81 in total

1.  [Severe autoimmune thrombopenia following anti-influenza vaccination].

Authors:  Hervé Granier; Xavier Nicolas; Jean-Pierre Laborde; François Talarmin
Journal:  Presse Med       Date:  2003-08-09       Impact factor: 1.228

2.  Immune thrombocytopenic purpura following influenza vaccination.

Authors:  Moshe Tishler; Ofer Levy; Mirit Amit-Vazina
Journal:  Isr Med Assoc J       Date:  2006-05       Impact factor: 0.892

3.  Idiopathic thrombocytopenic purpura and the second dose of MMR.

Authors:  Julia Stowe; George Kafatos; Nick Andrews; Elizabeth Miller
Journal:  Arch Dis Child       Date:  2007-10-25       Impact factor: 3.791

4.  Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?

Authors:  Anna C Bibby; Anna Farrell; Michelle Cummins; Michel Erlewyn-Lajeunesse
Journal:  Arch Dis Child       Date:  2008-04       Impact factor: 3.791

Review 5.  Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome.

Authors:  Daniel G Arkfeld; Ilene C Weitz
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

6.  Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpura.

Authors:  Naho Okazaki; Masahiro Takeguchi; Kohji Sonoda; Yohsuke Handa; Tatsuo Kakiuchi; Hiroaki Miyahara; Kensuke Akiyoshi; Seigo Korematsu; Soichi Suenobu; Tatsuro Izumi
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

7.  The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia.

Authors:  Andreia Maria Camargos Rocha; Cláudia Souza; Gifone Aguiar Rocha; Fabrício Freire de Melo; Nelma Cristina Diogo Clementino; Marília Campos Abreu Marino; Adriana Bozzi; Maria Luiza Silva; Olindo Assis Martins Filho; Dulciene Maria Magalhães Queiroz
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

8.  Development of fulminant Type 1 diabetes with thrombocytopenia after influenza vaccination: a case report.

Authors:  H Yasuda; M Nagata; H Moriyama; H Kobayashi; T Akisaki; H Ueda; K Hara; K Yokono
Journal:  Diabet Med       Date:  2012-01       Impact factor: 4.359

9.  Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients.

Authors:  U Nieminen; H Peltola; M T Syrjälä; A Mäkipernaa; R Kekomäki
Journal:  Acta Paediatr       Date:  1993-03       Impact factor: 2.299

10.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

View more
  39 in total

Review 1.  Menstrual abnormalities after COVID-19 vaccines: A systematic review.

Authors:  Maheen Nazir; Shumaila Asghar; Muhammad Ali Rathore; Asima Shahzad; Anum Shahid; Alishba Ashraf Khan; Asmara Malik; Tehniat Fakhar; Hafsa Kausar; Jahanzeb Malik
Journal:  Vacunas       Date:  2022-07-19

2.  The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination.

Authors:  Alfonso Ciccone; Bruno Zanotti
Journal:  Eur J Intern Med       Date:  2021-05-10       Impact factor: 7.749

3.  Temporal Association of Certain Neuropsychiatric Disorders Following Vaccination of Children and Adolescents: A Pilot Case-Control Study.

Authors:  Douglas L Leslie; Robert A Kobre; Brian J Richmand; Selin Aktan Guloksuz; James F Leckman
Journal:  Front Psychiatry       Date:  2017-01-19       Impact factor: 4.157

4.  SARS-CoV-2 vaccine-induced cerebral venous thrombosis.

Authors:  Alfonso Ciccone
Journal:  Eur J Intern Med       Date:  2021-05-25       Impact factor: 7.749

5.  Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?

Authors:  Federico Pasin; Alberto Calabrese; Laura Pelagatti
Journal:  Intern Emerg Med       Date:  2021-06-07       Impact factor: 5.472

Review 6.  Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.

Authors:  Syed Hamza Bin Waqar; Anosh Aslam Khan; Shehzeen Memon
Journal:  Int J Hematol       Date:  2021-07-15       Impact factor: 2.490

7.  COVID-19 vaccination associated severe immune thrombocytopenia.

Authors:  Syed Raza Ali Shah; Sherpa Dolkar; Jacob Mathew; Prakash Vishnu
Journal:  Exp Hematol Oncol       Date:  2021-07-15

8.  Immune Thrombocytopenic Purpura Cases Following COVID-19 Vaccination.

Authors:  Annalisa Condorelli; Uros Markovic; Roberta Sciortino; Mary Ann Di Giorgio; Daniela Nicolosi; Gaetano Giuffrida
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-03-01       Impact factor: 2.576

9.  Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.

Authors:  Ron Ram; David Hagin; Nino Kikozashvilli; Tal Freund; Odelia Amit; Yael Bar-On; Ofrat Beyar-Katz; Gabi Shefer; Miguel Morales Moshiashvili; Chen Karni; Ronit Gold; Sigi Kay; Chen Glait-Santar; Rinat Eshel; Chava Perry; Irit Avivi; Arie Apel; Noam Benyamini; David Shasha; Ronen Ben-Ami
Journal:  Transplant Cell Ther       Date:  2021-06-30

10.  First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.

Authors:  C R Simpson; T Shi; E Vasileiou; S V Katikireddi; S Kerr; E Moore; C McCowan; U Agrawal; S A Shah; L D Ritchie; J Murray; J Pan; D T Bradley; S J Stock; R Wood; A Chuter; J Beggs; H R Stagg; M Joy; R S M Tsang; S de Lusignan; R Hobbs; R A Lyons; F Torabi; S Bedston; M O'Leary; A Akbari; J McMenamin; C Robertson; A Sheikh
Journal:  Nat Med       Date:  2021-06-09       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.